Early Stage Partners
Venture capital firm founded in 2001 focused on investing in early-stage technology companies in the U.S. Midwest. ESP provides capital, advice and connections to support company growth and to generate returns for limited partners. The firm launched ESP Fund I (2002) and ESP Fund II (2008) and cites multiple exits, including a combined ~ $750M of portfolio exits in 2014.
Early Stage Partners
Services
Equity financing for early-stage companies
Provides venture capital to early-stage technology companies, including participation in Series rounds (examples: OnShift Series D participation; HistoSonics Series B participation).
Strategic advice and introductions
Provides portfolio companies with advisory support, mentorship and regional connections to accelerate company development and exits.
Limited partner services
Provides information and secure access for limited partners through an LP portal (eFileCabinet link).
Regional introductions and exit support
Assists portfolio companies with introductions to strategic acquirers and investors; highlights include participation in exits realized in 2014 (TOA Technologies, Simbionix, Reverse Medical).
Equity financing for early-stage companies
Provides venture capital to early-stage technology companies, including participation in Series rounds (examples: OnShift Series D participation; HistoSonics Series B participation).
Strategic advice and introductions
Provides portfolio companies with advisory support, mentorship and regional connections to accelerate company development and exits.
Limited partner services
Provides information and secure access for limited partners through an LP portal (eFileCabinet link).
Regional introductions and exit support
Assists portfolio companies with introductions to strategic acquirers and investors; highlights include participation in exits realized in 2014 (TOA Technologies, Simbionix, Reverse Medical).
Portfolio
Announced a joint development agreement with Archer Daniels Midland Company to develop and commercialize cavitation technology (April 26, 2017).
#Industrial / agricultural processing technology (hydrodynamic cavitation)
Developed TempTraq, a disposable Bluetooth wearable continuous temperature patch; study at Cleveland Clinic showed agreement with pulmonary artery catheter measurements; TempTraq integrated with TempTraq Connect (HIPAA-compliant) and used by University Hospitals during COVID-19 (April 20, 2020); system FDA, CE and TGA cleared (per site content).
#Wearable medical device / digital health (TempTraq continuous temperature monitor)
Developing Edison RAST platform (Robotically Assisted Sonic Therapy). ESP participated in financings including Series B (first close $8.3M, 2017). Company raised a $54M Series C in 2019 (reported on ESP site); received Frost & Sullivan 2019 North American Technology Innovation Award; recognized by The Observer among top healthcare startups.
#Medical device / therapeutic technology (histotripsy, non-invasive tumor ablation)
#Unknown (name only listed on ESP portfolio page)
ESP participated in multiple financing rounds. OnShift closed an $18M Series D on April 13, 2016 (Health Velocity Capital led; ESP participated). In October 2018 OnShift received a strategic equity investment led by Clearlake Capital with participation from earlier investors including ESP. OnShift reports thousands of customers (~5,000 referenced in a 2018 press release).
#Software / healthcare IT (human capital management for post-acute care and senior living)
#Materials / polymers (name listed on portfolio page)
Announced a joint development agreement with Archer Daniels Midland Company to develop and commercialize cavitation technology (April 26, 2017).
#Industrial / agricultural processing technology (hydrodynamic cavitation)
Developed TempTraq, a disposable Bluetooth wearable continuous temperature patch; study at Cleveland Clinic showed agreement with pulmonary artery catheter measurements; TempTraq integrated with TempTraq Connect (HIPAA-compliant) and used by University Hospitals during COVID-19 (April 20, 2020); system FDA, CE and TGA cleared (per site content).
#Wearable medical device / digital health (TempTraq continuous temperature monitor)
Developing Edison RAST platform (Robotically Assisted Sonic Therapy). ESP participated in financings including Series B (first close $8.3M, 2017). Company raised a $54M Series C in 2019 (reported on ESP site); received Frost & Sullivan 2019 North American Technology Innovation Award; recognized by The Observer among top healthcare startups.
#Medical device / therapeutic technology (histotripsy, non-invasive tumor ablation)
#Unknown (name only listed on ESP portfolio page)
ESP participated in multiple financing rounds. OnShift closed an $18M Series D on April 13, 2016 (Health Velocity Capital led; ESP participated). In October 2018 OnShift received a strategic equity investment led by Clearlake Capital with participation from earlier investors including ESP. OnShift reports thousands of customers (~5,000 referenced in a 2018 press release).
#Software / healthcare IT (human capital management for post-acute care and senior living)
#Materials / polymers (name listed on portfolio page)